NCT03363581 is a clinical trial of Food Preference in Obesity, sponsored by Imperial College London.

Who is sponsoring NCT03363581?

NCT03363581 is sponsored by Imperial College London.

What drugs are being tested in NCT03363581?

Interventions in NCT03363581: Food Preference.

Is NCT03363581 still recruiting?

NCT03363581 is currently completed. Last updated 8 August 2023.

Are results published for NCT03363581?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-08-08 · How we verify

NCT03363581

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Food Preference Following Bariatric Surgery

Completed Results posted Last updated 8 August 2023

What this trial tests

trial testing Food Preference in Obesity in 34 participants. Completed in 30 September 2021.

Timeline

15 December 2017

Primary endpoint
30 September 2021

30 September 2021

Quick facts

Lead sponsor	Imperial College London
Status	Completed
Study type	OBSERVATIONAL
Enrollment	34
Start date	15 December 2017
Primary completion	30 September 2021
Estimated completion	30 September 2021
Sites	1 location across Ireland

Drugs / interventions tested

Food Preference

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Imperial College London

Who can join

18 and older, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Total Food Intake (Lunch Buffet) at 24 Months Primary · 24 months

Determine the effect of RYGB on total food intake from an ad libitum lunch buffet

Group	Value	95% CI
Gastric Bypass	2540.1	± 431.0
Healthy Free-living Individuals	721	± 201

Change in Absolute Intake of Fat Primary · 24 months

Determine the effect of RYGB on food preferences by measuring the absolute i.e. total intake of fat from an ad libitum lunch buffet

Group	Value	95% CI
Gastric Bypass	-1549.7	± 298.9
Healthy Free-living Individuals	301	± 70.1

Change in Absolute Intake of Carbohydrates Primary · 24 months

Determine the effect of RYGB on food preferences by measuring the absolute i.e. total intake of carbohydrates from an ad libitum lunch buffet

Group	Value	95% CI
Gastric Bypass	-2088.6	± 370.1
Healthy Free-living Individuals	280	± 40.3

Change in Absolute Intake of Sugar Primary · 24 months

Determine the effect of RYGB on food preferences by measuring the absolute i.e. total intake of sugar from an ad libitum lunch buffet

Group	Value	95% CI
Gastric Bypass	-890.7	± 258.1
Healthy Free-living Individuals	160.0	± 39.8

Change in Absolute Intake of Protein Primary · 24 months

Determine the effect of RYGB on food preferences by measuring the absolute i.e. total intake of protein from an ad libitum lunch buffet

Group	Value	95% CI
Gastric Bypass	-360.7	± 91.4
Healthy Free-living Individuals	140.2	± 35.2

Sponsor's own description

Roux-en-Y gastric bypass (RYGB) decreases appetite, caloric intake, glycemia, and body weight, all of which are maintained long term.It is controversial whether, after RYGB, patients choose to eat less high fat and sugary foods in favor of lower energy dense alternatives. Therefore the proposition to use direct measures in humans after RYGB to test the hypothesis that the selection and intake of foods varying in fat content and glycemic index, as well as the pattern of ingestion within and across meals, changes in a manner that leads to beneficial outcomes on body weight.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03363581 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 8 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03363581.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing